635 related articles for article (PubMed ID: 14600260)
1. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes.
Smythe GM; Eby JC; Disatnik MH; Rando TA
J Cell Sci; 2003 Dec; 116(Pt 23):4739-49. PubMed ID: 14600260
[TBL] [Abstract][Full Text] [Related]
2. Loss of caveolin-3 induced by the dystrophy-associated P104L mutation impairs L-type calcium channel function in mouse skeletal muscle cells.
Couchoux H; Allard B; Legrand C; Jacquemond V; Berthier C
J Physiol; 2007 May; 580(Pt.3):745-54. PubMed ID: 17317753
[TBL] [Abstract][Full Text] [Related]
3. Altered caveolin-3 expression disrupts PI(3) kinase signaling leading to death of cultured muscle cells.
Smythe GM; Rando TA
Exp Cell Res; 2006 Sep; 312(15):2816-25. PubMed ID: 16814768
[TBL] [Abstract][Full Text] [Related]
4. Transgenic overexpression of caveolin-3 in the heart induces a cardiomyopathic phenotype.
Aravamudan B; Volonte D; Ramani R; Gursoy E; Lisanti MP; London B; Galbiati F
Hum Mol Genet; 2003 Nov; 12(21):2777-88. PubMed ID: 12966035
[TBL] [Abstract][Full Text] [Related]
5. Caveolae and caveolin-3 in muscular dystrophy.
Galbiati F; Razani B; Lisanti MP
Trends Mol Med; 2001 Oct; 7(10):435-41. PubMed ID: 11597517
[TBL] [Abstract][Full Text] [Related]
6. Caveolin scaffolding region and the membrane binding region of SRC form lateral membrane domains.
Wanaski SP; Ng BK; Glaser M
Biochemistry; 2003 Jan; 42(1):42-56. PubMed ID: 12515538
[TBL] [Abstract][Full Text] [Related]
7. Caveolins, caveolae, and lipid rafts in cellular transport, signaling, and disease.
Quest AF; Leyton L; Párraga M
Biochem Cell Biol; 2004 Feb; 82(1):129-44. PubMed ID: 15052333
[TBL] [Abstract][Full Text] [Related]
8. Modulation of myoblast fusion by caveolin-3 in dystrophic skeletal muscle cells: implications for Duchenne muscular dystrophy and limb-girdle muscular dystrophy-1C.
Volonte D; Peoples AJ; Galbiati F
Mol Biol Cell; 2003 Oct; 14(10):4075-88. PubMed ID: 14517320
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex.
Galbiati F; Volonte D; Minetti C; Chu JB; Lisanti MP
J Biol Chem; 1999 Sep; 274(36):25632-41. PubMed ID: 10464299
[TBL] [Abstract][Full Text] [Related]
10. Variable reduction of caveolin-3 in patients with LGMD2B/MM.
Walter MC; Braun C; Vorgerd M; Poppe M; Thirion C; Schmidt C; Schreiber H; Knirsch UI; Brummer D; Müller-Felber W; Pongratz D; Müller-Höcker J; Huebner A; Lochmüller H
J Neurol; 2003 Dec; 250(12):1431-8. PubMed ID: 14673575
[TBL] [Abstract][Full Text] [Related]
11. Two novel CAV3 gene mutations in Japanese families.
Sugie K; Murayama K; Noguchi S; Murakami N; Mochizuki M; Hayashi YK; Nonaka I; Nishino I
Neuromuscul Disord; 2004 Dec; 14(12):810-4. PubMed ID: 15564037
[TBL] [Abstract][Full Text] [Related]
12. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease.
Hnasko R; Lisanti MP
Mol Interv; 2003 Dec; 3(8):445-64. PubMed ID: 14993453
[TBL] [Abstract][Full Text] [Related]
13. Homozygous mutations in caveolin-3 cause a severe form of rippling muscle disease.
Kubisch C; Schoser BG; von Düring M; Betz RC; Goebel HH; Zahn S; Ehrbrecht A; Aasly J; Schroers A; Popovic N; Lochmüller H; Schröder JM; Brüning T; Malin JP; Fricke B; Meinck HM; Torbergsen T; Engels H; Voss B; Vorgerd M
Ann Neurol; 2003 Apr; 53(4):512-20. PubMed ID: 12666119
[TBL] [Abstract][Full Text] [Related]
14. Caveolin-3 is a direct molecular partner of the Cav1.1 subunit of the skeletal muscle L-type calcium channel.
Couchoux H; Bichraoui H; Chouabe C; Altafaj X; Bonvallet R; Allard B; Ronjat M; Berthier C
Int J Biochem Cell Biol; 2011 May; 43(5):713-20. PubMed ID: 21262376
[TBL] [Abstract][Full Text] [Related]
15. Association between the muscle-specific proteins desmin and caveolin-3 in muscle cells.
Mermelstein CS; Martins ER; Portilho DM; Costa ML
Cell Tissue Res; 2007 Feb; 327(2):343-51. PubMed ID: 17036228
[TBL] [Abstract][Full Text] [Related]
16. Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutanta and rescues wild-type caveolin-3.
Galbiati F; Volonte D; Minetti C; Bregman DB; Lisanti MP
J Biol Chem; 2000 Dec; 275(48):37702-11. PubMed ID: 10973975
[TBL] [Abstract][Full Text] [Related]
17. P-Glycoprotein is localized in intermediate-density membrane microdomains distinct from classical lipid rafts and caveolar domains.
Radeva G; Perabo J; Sharom FJ
FEBS J; 2005 Oct; 272(19):4924-37. PubMed ID: 16176266
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of volume-regulated anion channels by dominant-negative caveolin-1.
Trouet D; Hermans D; Droogmans G; Nilius B; Eggermont J
Biochem Biophys Res Commun; 2001 Jun; 284(2):461-5. PubMed ID: 11394902
[TBL] [Abstract][Full Text] [Related]
19. Caveolae facilitate but are not essential for platelet-activating factor-mediated calcium mobilization and extracellular signal-regulated kinase activation.
Poisson C; Rollin S; Véronneau S; Bousquet SM; Larrivée JF; Le Gouill C; Boulay G; Stankova J; Rola-Pleszczynski M
J Immunol; 2009 Aug; 183(4):2747-57. PubMed ID: 19620302
[TBL] [Abstract][Full Text] [Related]
20. Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease.
Betz RC; Schoser BG; Kasper D; Ricker K; Ramírez A; Stein V; Torbergsen T; Lee YA; Nöthen MM; Wienker TF; Malin JP; Propping P; Reis A; Mortier W; Jentsch TJ; Vorgerd M; Kubisch C
Nat Genet; 2001 Jul; 28(3):218-9. PubMed ID: 11431690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
